Skip to main content

COMPLEMENTO EN SALUD Y ENFERMEDAD

RED2022-134750-T

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Redes Investigación /Redes Excelencia
Call year 2022
State Plan 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The structure of Leptospira interrogans GAPDH sheds light into an immunoevasion factor that can target the anaphylatoxin C5a of innate immunity

  • Navas-Yuste, Sergio
  • De la Paz-García, Karla
  • Querol-García, Javier
  • Gómez, Sara
  • Rodríguez de Córdoba, Santiago
  • Fernández, Francisco J.
  • Vega, María Cristina
15 p.-7 fig.-4 tab., Leptospirosis is a neglected worldwide zoonosis involving farm animals and domestic pets caused by the Gram-negative spirochete Leptospira interrogans.This bacterium deploys a variety of immune evasive mechanisms, some of them targeted at the complement system of the host’s innate immunity. In this work, we have solved the X-ray crystallographic structure of L. interrogans glyceraldehyde-3-phosphate dehydrogenase (GAPDH) to 2.37-Å resolution, a glycolytic enzyme that has been shown to exhibit moonlighting functions that potentiate infectivity and immune evasion in various pathogenic organisms.Besides, we have characterized the enzyme’s kinetic parameters toward the cognate substrates and have proven that the two natural products anacardic acid and curcumin are able to inhibit L. interrogans GAPDH at micromolar concentration through a noncompetitive inhibition modality. Furthermore, we have established that L. interrogans GAPDH can interact with the anaphylatoxin C5a of human innate immunity in vitro using bio-layer interferometry and a short-range cross-linking reagent that tethers free thiol groups in protein complexes. To shed light into the interaction between L. interrogans GAPDH and C5a, we have also carried out cross-link guided protein-protein docking. These results suggest that L. interrogans could be placed in the growing list of bacterial pathogens that exploit glycolytic enzymes as extracellular immune evasive factors. Analysis of the docking results indicates a low affinity interaction that is consistent with previous evidence, including known binding modes of other a-helical proteins with GAPDH. These findings allow us to propose L. interrogans GAPDH as a potential immune evasive factor targeting the complement system., This work was funded by Spanish Ministerio de Ciencia, Innovación y Universidades-FEDER grants RTI2018-102242-B-I00 (to MCV) and PID2019-104912RB-I00 (to SRdC); and the Spanish Ministerio de Ciencia e Innovación-Recovery, Transformation and Resilience Plan (PRTR) grant PDC2022-133713-I00. It was also funded by Grants S2017/BMD-3673 and S2022/BMD-7278 of the Regional Government of Madrid and the European Commission – NextGenerationEU through CSIC’s Global Health Platform (“PTI Salud Global”) (SGL2103020) (to SRdC and MCV), and the CSIC Special Intramural Grant PIE-201620E064 (to MCV). It was additionally supported by the Research Network on Complement in Health and Disease (RED2022-134750-T). SRdC was also supported by the CIBER de Enfermedades Raras. KdlP was supported by an Industrial PhD grant (IND2018-010094) awarded by the Spanish Ministerio de Economía y Competitividad., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Structural biology of complement receptors

  • Santos-López, Jorge
  • De la Paz-García, Karla
  • Fernández, Francisco J.
  • Vega, María Cristina
25 p.-6 fig.-1 tab., The complement system plays crucial roles in a wide breadth of immune and inflammatory processes and is frequently cited as an etiological or aggravating factor in many human diseases, from asthma to cancer. Complement receptors encompass at least eight proteins from four structural classes, orchestrating complement-mediated humoral and cellular effector responses and coordinating the complex cross-talk between innate and adaptive immunity.The progressive increase in understanding of the structural features of the main complement factors, activated proteolytic fragments, and their assemblies have spurred a renewed interest in deciphering their receptor complexes. In this review, we describe what is currently known about the structural biology of the complement receptors and their complexes with natural agonists and pharmacological antagonists. We highlight the fundamental concepts and the gray areas where issues and problems have been identified, including current research gaps. We seek to offer guidance into the structural biology of the complement system as structural information underlies fundamental and therapeutic research endeavors. Finally, we also indicate what we believe are potential developments in the field., This work was funded by Grants PDC2022-133713-I00 of the Spanish Ministerio de Ciencia e Innovación-Recovery,Transformation and Resilience Plan (PRTR), S2022/BMD-7278 of the Regional Government of Madrid, and the European Commission – NextGenerationEU through CSIC’s Global Health Platform (“PTI Salud Global”) (SGL2103020) (to MCV), and the CSIC Special Intramural Grant PIE-201620E064 (to MCV). It was additionally supported by the Network of Excellence Complement in Health and Disease (RED2022-134750-T). KdlP was supported by the Industrial Ph.D. Doctorate (DIN2018-010094) of the Spanish Ministry of Economy and Innovation., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Data-augmented machine learning refines the effective-concentration estimate for eculizumab in complement-mediated diseases

  • Fernández, Francisco J.
  • Alfonso-González, Lucía
  • Praga, Manuel
  • Mikkelsen, Kaare
  • Vega, María Cristina
Eculizumab, a humanized monoclonal antibody targeting the complement protein C5, is highly efficient in paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disorder. However, recent reports have highlighted a subset of patients who show inadequate treatment response, prompting dose escalation or interval shortening. The serum concentration required for sustained inhibition of the complement lytic pathway remains uncertain, and the commonly cited 50-100 µg/ml range is not grounded in robust pharmacokinetic-pharmacodynamic data. Using publicly available clinical data digitized from four rare indications, we trained machine-learning supervised classifiers to predict complete C5 inhibition as a function of serum eculizumab concentration, identifying logistic regression on log-transformed concentration as the best and mechanistically appropriate model on real data. We then examined whether augmenting the real training data with high-fidelity synthetic data improves the resulting estimate. Although augmentation did not significantly change balanced accuracy, it reduced the confidence interval for the effective concentration by roughly 12-fold (a 92% reduction). The augmentation-stabilized estimate of the concentration associated with complete C5 inhibition was approximately 310.8-335.2 µg/ml (real-data-only estimate 338 µg/ml, 95% CI 275-454). These data-driven, hypothesis-generating results indicate that current maintenance targets aimed at near-complete C5 suppression may be substantially underestimated and that faithful synthetic augmentation can improve the precision of model-based pharmacological estimates in rare diseases; prospective validation in independent cohorts is required before any clinical application., The author(s) declared that financial support was received for this work and/or its publication. This work was funded by the Spanish Ministerio de Ciencia e Innovación-Recovery, Transformation and Resilience Plan (PRTR) grants PDC2022-133713-I00 (MV) and CPP2022-009838 (FF); grant S2022/BMD-7278 from the Regional Government of Madrid (MV); the European Commission – NextGenerationEU through CSIC’s Global Health Platform (“PTI Salud Global”) (SGL2103020) (MV); and the Instituto de Salud Carlos III (ISCIII) grant PI24/00925 (MV). It was also supported by the Research Network on Complement in Health and Disease (RED2022-134750-T) (MV). LA-G received support through an Industrial PhD grant (IND2019/BMD-17219) from the Regional Government of Madrid (FF and MV)., Peer reviewed